Preview

Злокачественные опухоли

Расширенный поиск

КРИТЕРИИ ОЦЕНКИ ЭФФЕКТИВНОСТИ НЕОАДЪЮВАНТНЫХ И АДЪЮВАНТНЫХ МЕТОДОВ ЛЕЧЕНИЯ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ

https://doi.org/10.18027/2224-5057-2013-3-35-41

Полный текст:

Аннотация

За последние 10 лет неоадъювантная химиотерапия заняла свое полноправное место в лечении рака молочной железы (РМЖ). Клинические исследования показали, что женщины, у которых достигнут полный патоморфологический регресс опухоли (рCR), характеризуются существенным улучшением показателей выживаемости по сравнению с теми, у кого не достигнут столь выраженный регресс. Мета-анализ, проведенный по заданию FDA (Food and Drug Administration), показал, что достижение полного патоморфологического ответа (pCR) как промежуточ-ного маркера улучшения выживаемости, наблюдается в основном у женщин с агрессивными подтипами рака молочной железы: трижды негативным и HER2-позитивным РМЖ. У пациентов с HER2+ РМЖ дополнение трастузумаба к неоадъювантной химиотерапии удваивает частоту рCR и коррелирует с повышением показателей выживаемости.

Об авторах

В. Г. Иванов
ФГБУ НИИ онкологии им. Н. Н. Петрова Минздрава России
Россия


Е. К. Жильцова
ФГБУ НИИ онкологии им. Н. Н. Петрова Минздрава России
Россия


О. А. Иванова
ФГБУ НИИ онкологии им. Н. Н. Петрова Минздрава России
Россия


Н. Ю. Бараш
ФГБУ НИИ онкологии им. Н. Н. Петрова Минздрава России
Россия


Список литературы

1. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. / Clin Oncol. 2006.-vol.24. — pp.2019-2027.

2. Rastogi P, Andcrson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols В-18 and B-27. / Clin Oncol. 2008. vol.26.-pp.778-785.

3. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR.Pathological assessment of response to induction chemotherapy in

4. breast cancer. Cancer Res. 1986. — vol.46. — pp.2578-2581.

5. Hortobagyi GN, Ames PC, Buzdar AU, et al. Management of stage III

6. primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer. 1988.-vol.62.-2507-2516.

7. Fisher В, Bryant J, Wolmark N, et al. Effect of preoperative chemotherару on the outcome of women with operable breast cancer. / Clin Oncol. 1998.-vol.16. — pp.2672-2685.

8. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable

9. breast cancer: eight-year experience at the Milan Cancer Institute. / Clin Oncol. 1998.-vol.16. — pp.93-100.

10. Von Minckwitz G, Untch M, Blohmer J, et al. Definition and impact of

11. pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. / Clin Oncol. 2012. — vol. 30.-pp.1796-1804.

12. Esserman LJ, Berry DA, DeMichele A, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results froix the I-SPY 1 I’RIAL-CALGB 150007 / 150012, ACRIN 6657. / Clin Oncol. 2012. — vol 30. — pp.3242-3249.

13. Boughey C, Suman VJ, Mittendorf EA, et al. The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (TO-T4, N1-2) who receive neoadjuvant chemotherapy — results from the ACOSOG Z1071 trial. Cancer Res. 2012, 72 (24 suppl): Abstr S2–1.

14. Kuehn T, Bauerfeind IGP, Fehm T, et al. Sentinel lymph node biopsy

15. before or after neoadjuvant chemotherapy-final results from the Prospective German, multiinstitutional SENTINA-Trial. Cancer Res. 2012.-vol. 72 (24 Suppl.): Abstr S2–2.

16. Mamounas EP, Anderson SJ, Dignam)), etal. Predictorsoflocoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. / Clin Oncol. 2012.-vol.30.-pp3960–3966.

17. Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl) Med. 2012.-vol.366. — pp.310-320.

18. Ellis MJ, Tao Y, Luo J, et al. Outcome prediction for estrogen receptorpositive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. / Natl Cancer Inst. 2008.-vol.100.-pp.1380-1388.

19. Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAMSO-based intrinsic subtype-ACOSOG Z1031. JClin Oncol. 2011.-vol.29. — pp.2342-2349.

20. Sorlie T. Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001 vol. 98 pp.10869-10874.

21. Bhargava R, Beriwal S, Dabbs DJ, et al. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases. Cancer 2010 vol. 116 pp.1431-1439.

22. Cheang MC. Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal В breast cancer. / Nutl Cancer inst. 2009 vol. 101 pp. 736-750.

23. Dawood S, Hu R, Homes MD, et al. Defining breast cancer prognosis based on molecular phenotypes: Results from a large cohort study. Breast Cancer Res Treat. 2011 vol. 126 pp. 185-192.

24. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes— dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Onco / . 2001 vol. 22 pp.1736-1747.

25. Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.; Clin Oncol. 2. 2006 vol. 24 pp. 5381-5387.

26. Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without inserval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project R-1 5. / Clin Oncol. 1990 vol. 8 pp. 1483-1496.

27. Shulman LN, Cirrincione CT, Berry DA, et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group В 40101 / Clin Oncol. 2012 vol. 30 pp. 4071-4076.

28. Tavassoli FA, Devilee Р (cds). Pathology 6- Genetics ofTumours of the Breast and Female Genital Organs. Lyon; International Agency for Research on Cancer Press; 2003.

29. Byrski T, Gronwald], Huzarski Т, et al. Pathologic complete response rates in young women with BRCA 1-positive breast cancers after neoadjuvant chemotherapy. / Clin Oncol. 2010 vol. 28 pp.375-379.

30. Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer, / Clin Oncol. 2010 vol. 28 pp.1145-1153.

31. Anders CK, Hsu DS. Broadwater G, et a1. Young age at diagnose correlates with worse prognosis and defines a subset of breast cancer with shared patterns of gene expression. / Clin Oncol 2008; vol. 26 pp. 3324-3330.

32. Muss HB. Adjuvant treatment of elderly breast cancer patients. Brea: 16 Suppl. 2007; 2: S159-S165.


Для цитирования:


Иванов В.Г., Жильцова Е.К., Иванова О.А., Бараш Н.Ю. КРИТЕРИИ ОЦЕНКИ ЭФФЕКТИВНОСТИ НЕОАДЪЮВАНТНЫХ И АДЪЮВАНТНЫХ МЕТОДОВ ЛЕЧЕНИЯ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ. Злокачественные опухоли. 2013;(3):35-41. https://doi.org/10.18027/2224-5057-2013-3-35-41

For citation:


Ivanov V.G., Zhil'tsova E.K., Ivanova O.A., Barash N.Y. Evaluation criteria of neoadjuvant and adjuvant methods of treatment of breast cancer. Malignant tumours. 2013;(3):35-41. (In Russ.) https://doi.org/10.18027/2224-5057-2013-3-35-41

Просмотров: 738


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2224-5057 (Print)
ISSN 2587-6813 (Online)